Total submissions: 16
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000790804 | SCV000232484 | pathogenic | not provided | 2014-01-21 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000208605 | SCV000695977 | pathogenic | Mucopolysaccharidosis type 1 | 2017-08-02 | criteria provided, single submitter | clinical testing | Variant summary: The IDUA c.979G>C (p.Ala327Pro) variant involves the alteration of a non-conserved nucleotide located in the Glycoside hydrolase superfamily domain (IPR017853) (InterPro). 2/3 in silico tools predict a benign outcome for this variant (SNPsandGO and MutationTaster not captured due to low reliability index and p-value, respectively). Functional studies found very low enzymatic residual activity in homozygote and compound heterozygote MPS I patients (Oussorena__2013, Yogalingam_2004). The variant of interest has been found in a large, broad control population, ExAC in 7/90286 control chromosomes at a frequency of 0.0000775, which does not exceed the estimated maximal expected allele frequency of a pathogenic IDUA variant (0.0026926). This variant was found in multiple patients with MPS I, including homozygotes and compound heterozygotes (in trans with pathogenic variants such as c.878-889dup12, c.1205G>A/p.W402X, c.1154C>G/p.P385R, and c.1148G>A/R383H), and determined to be associated with a severe phenotype. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic. |
Counsyl | RCV000180108 | SCV000791720 | pathogenic | Hurler syndrome | 2017-05-22 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000208605 | SCV000834627 | pathogenic | Mucopolysaccharidosis type 1 | 2024-10-16 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 327 of the IDUA protein (p.Ala327Pro). This variant is present in population databases (rs199801029, gnomAD 0.01%). This missense change has been observed in individual(s) with mucopolysaccharidosis type I (PMID: 7550242, 15300847, 19396826, 23786846, 24368159). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is also known as c.1067G>C. ClinVar contains an entry for this variant (Variation ID: 167190). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed for this missense variant. However, the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on IDUA protein function. Experimental studies have shown that this missense change affects IDUA function (PMID: 15300847, 23786846). For these reasons, this variant has been classified as Pathogenic. |
Laboratory of Diagnosis and Therapy of Lysosomal Disorders, |
RCV000208605 | SCV000929873 | likely pathogenic | Mucopolysaccharidosis type 1 | 2019-01-01 | criteria provided, single submitter | literature only | PS3: Low in vivo enzymatic activity in homozygote. PM2: Very low frequency in GnomAD |
UNC Molecular Genetics Laboratory, |
RCV000208605 | SCV001251528 | pathogenic | Mucopolysaccharidosis type 1 | criteria provided, single submitter | research | The IDUA c.979G>C (p.A327P) variant was reported in the compound heterozygous state in at least 4 patients with MPS I (PMID: 7550242; 112203999; 15300847; 19396826; 24368159). | |
Broad Center for Mendelian Genomics, |
RCV000208605 | SCV001422985 | pathogenic | Mucopolysaccharidosis type 1 | 2020-01-13 | criteria provided, single submitter | curation | The p.Ala327Pro variant in IDUA has been reported in at least 23 individuals with mucopolysaccharidosis (MPS) (PMID: 28752568, 23786846, 7550242, 19396826, 24368159) and has been identified in 0.012% (15/123926) of European (non-Finnish) chromosomes, 0.006% (2/34992) of Latino chromosomes, and 0.004% (1/24138) of African chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs199801029). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a recessive carrier frequency. This variant has also been reported in ClinVar (VariationID: 167190) as pathogenic by Counsyl, EGL Genetic Diagnostics, Integrated Genetics, Invitae, and GeneReviews. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. The phenotype of individuals homozygous and compound heterozygous for this variant is highly specific for MPS based on their Alpha-L-iduronidase levels being <1% of normal consistent with disease (PMID: 23786846). The presence of this variant in 3 affected homozygotes and in combination with a reported pathogenic variant in at least 14 individuals with MPS increases the likelihood that the p.Ala327Pro variant is pathogenic (VariationID: 11908; PMID: 28752568, 23786846, 7550242, 19396826). In summary, this variant meets criteria to be classified as pathogenic for MPS in an autosomal recessive manner based on multiple occurrences in combination with other pathogenic variants in individuals with MPS and the phenotype of patients with the variant being highly specific for disease. ACMG/AMP Criteria applied: PM3_very-strong, PM2_supporting, PP4 (Richards 2015). |
Johns Hopkins Genomics, |
RCV000180108 | SCV001425318 | pathogenic | Hurler syndrome | 2020-04-29 | criteria provided, single submitter | clinical testing | This IDUA variant has been previously reported in patients with mucopolysaccharidosis I in the presence of a second known disease-causing variant. Although the alanine residue at this position is not evolutionarily conserved across species assessed, funcational analysis in patient cells support that c.979G>C results in reduced IDUA ensymatic activity. This variant (rs199801029) is rare (<0.1%) in a large population dataset (gnomAD: 19/273938 total alleles; 0.006936%; no homozygotes). Six submitters in ClinVar6 classify this variant as either pathogenic or likely pathogenic. We consider it to be pathogenic. |
Gene |
RCV000790804 | SCV001796972 | pathogenic | not provided | 2020-02-07 | criteria provided, single submitter | clinical testing | Not observed at a significant frequency in large population cohorts (Lek et al., 2016); This variant is associated with the following publications: (PMID: 31589614, 30809705, 27896125, 8680403, 21394825, 27392569, 27511503, 28684085, 28752568, 10607946, 23786846, 9427149, 7550242, 24368159, 7951228, 15300847) |
Revvity Omics, |
RCV000790804 | SCV002023111 | pathogenic | not provided | 2023-06-06 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000790804 | SCV005041606 | pathogenic | not provided | 2024-04-01 | criteria provided, single submitter | clinical testing | IDUA: PM3:Very Strong, PM2, PS3:Supporting |
Fulgent Genetics, |
RCV005031662 | SCV005667764 | pathogenic | Mucopolysaccharidosis, MPS-I-S; Hurler syndrome; Mucopolysaccharidosis, MPS-I-H/S | 2024-05-24 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000208605 | SCV000264382 | not provided | Mucopolysaccharidosis type 1 | no assertion provided | literature only | Common pathogenic variant in Europe | |
Natera, |
RCV000208605 | SCV001461759 | pathogenic | Mucopolysaccharidosis type 1 | 2020-09-16 | no assertion criteria provided | clinical testing | |
Diagnostic Laboratory, |
RCV000790804 | SCV001740921 | pathogenic | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000790804 | SCV001975512 | pathogenic | not provided | no assertion criteria provided | clinical testing |